Eric Fernandez, MD
Family Medicine · Evanston, ILNPI 1063874410
Payments from drug & device makers
Across 219 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$859
- AbbVie$570
- AstraZeneca$381
- GSK$322
- Novo Nordisk$260
- Boehringer Ingelheim$224
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,659100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 52 | $859 |
| AbbVie | 35 | $570 |
| AstraZeneca | 21 | $381 |
| GSK | 19 | $322 |
| Novo Nordisk | 19 | $260 |
| Boehringer Ingelheim | 13 | $224 |
| Pfizer | 10 | $179 |
| Bayer | 8 | $134 |
| Merck | 7 | $97 |
| Astellas Pharma US Inc | 4 | $73 |
| Xeris Pharmaceuticals, Inc. | 3 | $64 |
| Vanda Pharmaceuticals Inc. | 2 | $54 |
| Abbott | 2 | $48 |
| Dexcom, Inc. | 2 | $41 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Sanofi-aventis U.S. LLC | 2 | $32 |
| Novartis | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $29 |
| Lundbeck LLC | 1 | $24 |
| Amgen | 1 | $22 |
| Inspire Medical Systems, Inc. | 1 | $19 |
| Phadia US Inc. | 1 | $19 |
| Impel Pharmaceuticals Inc. | 1 | $16 |
| Scilex Pharmaceuticals Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Vertex | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Dynavax Technologies Corporation | 1 | $13 |
How this compares
$3,674 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 132 | $233,620 |
| JardianceEmpagliflozin | 72 | $110,101 |
| FarxigaDapagliflozin Propanediol | 80 | $93,747 |
| MounjaroTirzepatide | 36 | $71,150 |
| EliquisApixaban | 45 | $60,559 |
| LinzessLinaclotide | 38 | $50,545 |
| JanuviaSitagliptin Phosphate | 37 | $47,534 |
| TrulicityDulaglutide | 13 | $30,429 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $25,172 |
| TradjentaLinagliptin | 16 | $23,537 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $22,723 |
| Breo ElliptaFluticasone/Vilanterol | 52 | $22,016 |
| ProliaDenosumab | 11 | $19,126 |
| EntrestoSacubitril/Valsartan | 18 | $14,893 |
| VascepaIcosapent Ethyl | 20 | $14,294 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $260 | $233,620132 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr | $224 | $147,740104 claims |
| Lilly USA, LLCMounjaro, Trulicity | $859 | $101,57849 claims |
| AstraZenecaFarxiga | $381 | $93,74780 claims |
| PfizerEliquis | $179 | $60,55945 claims |
| AbbVieLinzess, Synthroid | $570 | $52,41058 claims |
| MerckJanuvia | $97 | $47,53437 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $322 | $44,73986 claims |
| AmgenProlia | $22 | $19,12611 claims |
| NovartisEntresto | $32 | $14,89318 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $16 | $2,39013 claims |
| Sanofi-aventis U.S. LLCLantus | $32 | $2,38829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Evanston
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
- Mark ChristensenNew Lenox$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.